Medical information Clinical review pending

Genetic Testing

DNAI2 Gene Primary Ciliary Dyskinesia Type 9 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the DNAI2 gene for mutations associated with Primary Ciliary Dyskinesia (PCD) Type 9, a condition affecting respiratory health.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: A blood sample is required for this test. Confirm specific volume and collection tube requirements with the laboratory before booking.
Results: Confirm turnaround time with the laboratory before booking.
Preparation: No special preparation is typically required for a blood draw. However, confirm with the laboratory if any specific instructions apply.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the DNAI2 Gene Primary Ciliary Dyskinesia Type 9 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Chronic respiratory infections (e.g., bronchitis, pneumonia)
✓Persistent cough
✓Chronic sinusitis
✓Otitis media (middle ear infections)
✓Hearing loss
✓Male infertility
✓Family history of Primary Ciliary Dyskinesia
✓Situs inversus (organs reversed)

In plain language

What this test helps you understand

This test helps identify mutations in the DNAI2 gene associated with Primary Ciliary Dyskinesia (PCD) Type 9. It aids in the diagnosis of PCD, particularly in individuals with symptoms suggestive of the condition or a family history of PCD. Accurate diagnosis allows for appropriate management, surveillance for complications, and genetic counseling for affected individuals and their families.

The DNAI2 Gene Primary Ciliary Dyskinesia Type 9 NGS Genetic DNA Test is a diagnostic tool used to identify Primary Ciliary Dyskinesia (PCD), a genetic disorder affecting the function of cilia, which are tiny hair-like structures in the body. PCD can lead to chronic respiratory problems, sinus infections, and other health issues. This test analyzes the DNAI2 gene, mutations in which are known to cause a specific type of PCD. Understanding your genetic makeup can help healthcare providers diagnose PCD accurately and develop appropriate management strategies. This test utilizes advanced Next-Generation Sequencing (NGS) technology for precise analysis.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is typically required for a blood draw. However, confirm with the laboratory if any specific instructions apply.

SampleA blood sample is required for this test. Confirm specific volume and collection tube requirements with the laboratory before booking.

MethodologyNext-Generation Sequencing (NGS) is used to analyze the DNA sequence of the DNAI2 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the DNAI2 gene. PCD can be caused by mutations in other genes, which are not assessed by this test. A negative result does not completely rule out PCD if clinical suspicion remains high. The test may not detect all possible mutations within the DNAI2 gene. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

PCD is a rare, inherited genetic disorder that affects the cilia, tiny hair-like structures lining the airways, sinuses, and other parts of the body. Defective cilia lead to chronic respiratory infections, sinus problems, and sometimes infertility or hearing loss.

This test specifically looks for mutations (changes) in the DNAI2 gene, which is one of the genes known to cause PCD. It uses advanced DNA sequencing technology.

Individuals experiencing persistent respiratory symptoms like chronic cough, recurrent lung infections, or chronic sinusitis, especially if they have a family history of similar issues or related conditions like infertility or situs inversus, may be candidates for this test.

Results will indicate if specific mutations associated with PCD Type 9 were found in the DNAI2 gene. It is highly recommended to discuss the results with a healthcare provider or genetic counselor to understand their meaning and implications.

Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.

Turnaround time can vary. Please contact the laboratory for the most current estimated timeframe.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp